1159831-86-3

Usage

Uses

Used in Pharmaceutical Synthesis:
6-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylic acid is utilized as a key intermediate in the development of new pharmaceuticals due to its unique structure and reactivity, which allows for the creation of diverse drug candidates with potential therapeutic applications.
Used in Agrochemical Development:
In the agrochemical industry, 6-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylic acid is employed as a precursor in the synthesis of novel compounds with pesticidal properties, leveraging its structural attributes to combat various agricultural pests and diseases.
Used in Antimicrobial Agents:
6-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylic acid is studied for its potential as an antimicrobial agent, given its ability to inhibit the growth of bacteria, which could be harnessed in the development of new antibiotics or disinfectants.
Used in Antifungal Compositions:
6-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylic acid is also being investigated for its antifungal properties, making it a candidate for use in antifungal medications or treatments to control fungal infections in various settings.
Used in Antiviral Therapies:
6-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylic acid is considered for its potential role in antiviral therapies, as its structure may offer avenues for inhibiting viral replication or infectivity, contributing to the development of new antiviral drugs.
These applications highlight the versatility and potential impact of 6-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylic acid across different sectors, particularly in the creation of new and effective therapeutic and protective agents.

Relevant academic research and scientific papers

Design, Synthesis, and Preclinical Efficacy of Novel Nonretinoid Antagonists of Retinol-Binding Protein 4 in the Mouse Model of Hepatic Steatosis

Retinol-binding protein 4 (RBP4) serves as a transporter for all-trans-retinol (1) in the blood, and it has been proposed to act as an adipokine. Elevated plasma levels of the protein have been linked to diabetes, obesity, cardiovascular diseases, and nonalcoholic fatty liver disease (NAFLD). Recently, adipocyte-specific overexpression of RBP4 was reported to cause hepatic steatosis in mice. We previously identified an orally bioavailable RBP4 antagonist that significantly lowered RBP4 serum levels in Abca4-/- knockout mice with concomitant normalization of complement system protein expression and reduction of bisretinoid formation within the retinal pigment epithelium. We describe herein the discovery of novel RBP4 antagonists 48 and 59, which reduce serum RBP4 levels by >80% in mice upon acute oral dosing. Furthermore, 59 demonstrated efficacy in the transgenic adi-hRBP4 murine model of hepatic steatosis, suggesting that RBP4 antagonists may also have therapeutic utility for the treatment of NAFLD.

BICYCLIC LACTAMS AND METHODS OF USE THEREOF

The invention provides novel compounds having the general formula I: (I) wherein R1, X, Z1, L, n, the A ring, the B ring, and the C ring are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.

SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARAITON AND USE

The present invention provides a compound having the structure: wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl, wherein two or more of R1, R2, R3, R4, or R5 are other than H; R6 is H, OH, or halogen; and B is a substituted or unsubstituted heterobicycle, wherein when R1 is CF3, R2 is H, R3 is F, R4 is H, and R5 is H, or R1 is H, R2 is CF3, R3 is H, R4 is CF3, and R5 is H, or R1 is C1, R2 is H, R3 is H, R4 is F, and R5 is H, or R1 is CF3, R2 is H, R3 is F, R4 is H, and R5 is H, or R1 is CF3, R2 is F, R3 is H, R4 is H, and R5 is H, or R1 is C1, R2 is F, R3 is H, R4 is H, and R5 is H, then B is other than or a pharmaceutically acceptable salt thereof.

OCTAHYDROPYRROLOPYRROLES, THEIR PREPARATION AND USE

The present invention provides compounds comprising variously substituted octahydropyrrolopyrroles, their synthesis, methods of making, methods of using, compositions and formulations thereof.